Completed PHASE3 INTERVENTIONAL NCT00144378

Irinotecan Versus Only Best Supportive Care for Gastric Cancer

Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer

Sponsor: Charite University, Berlin, Germany

Conditions Neoplasm Metastasis Stomach Neoplasm

Interventions Irinotecan

Updated 5 times since 2017 Last updated: Apr 17, 2007 Started: Oct 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Neoplasm Metastasis and Stomach Neoplasm and is currently completed. Charite University, Berlin, Germany leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany